BCL2 and cancer: Martucci et al. modified DNPs with a mean diameter of 370 ± 20 nm with an Id-peptide recognized by the B-cell receptor (BCR) for the targeted delivery of the anti-Bcl-2 siRNA (DNPs-siRNA) into cancer cells [60] (Table 1).